Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAM | P19021 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.46 |
| ▸ | PPID | Q08752 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6511742 | 1.00 | PAM (0.51) | PAML3MBTL1SMN1; SMN2NPC1PKM | |
| SCHEMBL68412 | 0.93 | L3MBTL1 (0.50) | PAML3MBTL1SMN1; SMN2NPC1PKM | |
| Phenylacetic Acid SCHEMBL28334050 | 0.89 | PAM (0.65) | PAML3MBTL1SMN1; SMN2NPC1PKM | |
| SCHEMBL1515865 | 0.88 | L3MBTL1 (0.49) | PAML3MBTL1SMN1; SMN2NPC1PKM | |
| SCHEMBL1810196 | 0.87 | L3MBTL1 (0.47) | PAML3MBTL1SMN1; SMN2NPC1PKM | |
| SCHEMBL1401401 | 0.86 | L3MBTL1 (0.46) | PAML3MBTL1SMN1; SMN2NPC1PKM | |
| SCHEMBL2457851 | 0.86 | SLC7A5 (0.47) | PAML3MBTL1SMN1; SMN2NPC1PKM | |
| SCHEMBL5034285 | 0.85 | CYP4Z1 (0.59) | PAML3MBTL1SMN1; SMN2NPC1PKM | |
| SCHEMBL2630609 | 0.85 | PPARA (0.51) | PAML3MBTL1SMN1; SMN2NPC1PKM | |
| SCHEMBL5725282 | 0.85 | LOXL2 (0.49) | PAML3MBTL1SMN1; SMN2NPC1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113549010-B | Preparation and application of compound with AMPK (AMPK) agonistic activity and prodrug thereof | 中国科学院上海药物研究所 | 2023-10-20 | — | — | CN | disclosed |
| CN-113549010-A | Preparation and application of compound with AMPK agonistic activity and prodrug thereof | 中国科学院上海药物研究所 | 2021-10-26 | — | — | CN | disclosed |
| US-20200165238-A1 | Heterocyclic Inhibitors of Glutaminase | CALITHERA BIOSCIENCES INC. | 2020-05-28 | — | — | US | disclosed |
| US-20190315733-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. | 2019-10-17 | — | — | US | disclosed |
| EP-2782570-B1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC (US) | 2019-09-18 | — | — | EP | disclosed |
| US-9938267-B2 | Heterocyclic inhibitors of glutaminase | CALITHERA BIOSCIENCES, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20150004134-A1 | TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES, INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20140369961-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. | 2014-12-18 | — | — | US | disclosed |
| US-20140050699-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20130157998-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20050215590-A1 | Formamide derivatives for the treatment of diseases | PFIZER LIMITED (GB) | 2005-09-29 | — | — | US | disclosed |
| US-20050215542-A1 | Compounds for the treatment of diseases | PFIZER INC | 2005-09-29 | — | — | US | disclosed |
| EP-1574501-A1 | Quinolinone derivatives, pharmaceutical compositions containing them and their use | Pfizer Limited (GB) | 2005-09-14 | — | — | EP | disclosed |
| WO-2005080324-A1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
| US-20050171147-A1 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC. | 2005-08-04 | — | — | US | disclosed |
| US-20050014763-A1 | 2-Amino-pyridine derivatives useful for the treatment of diseases | PFIZER INC | 2005-01-20 | — | — | US | disclosed |
| WO-2004108676-A1 | 2-(6-AMINO-PYRIDIN-3-YL)-2-HYDROXYETHYLAMINE DERIVATIVES AS BETA 2-ADRENOCEPTORS AGONISTS | PFIZER LIMITED (GB) | 2004-12-16 | — | — | WO | disclosed |
| EP-0714893-B1 | 2-substituted benzothiazole derivatives useful in the treatment of diabetic complications | GRELAN PHARMACEUTICAL CO (JP) | 1998-10-21 | — | — | EP | disclosed |
| US-5700819-A | ALDOSE REDUCTASE ENZYME INHIBITOR | GRELAN PHARMACEUTICAL CO., LTD. (JP) | 1997-12-23 | — | — | US | disclosed |
| EP-0714893-A1 | 2-substituted benzothiazole derivatives useful in the treatment of diabetic complications | GRELAN PHARMACEUTICAL CO., LTD. (JP) | 1996-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140050699-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | PAM 1568/4885L3MBTL1 4146/4885SMN1; SMN2 4375/4885 |
| US-20190315733-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | PAM 1568/4885L3MBTL1 4146/4885SMN1; SMN2 4375/4885 |
| US-20050014763-A1 | 2-Amino-pyridine derivatives useful for the treatment of diseases | PAH, AADAT, IL4I1 | PAM 206/4885L3MBTL1 4476/4885SMN1; SMN2 2010/4885 |
| US-20200165238-A1 | Heterocyclic Inhibitors of Glutaminase | GLS, GLS2, GLUL | PAM 1568/4885L3MBTL1 4146/4885SMN1; SMN2 4375/4885 |
| US-20140369961-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | PAM 1568/4885L3MBTL1 4146/4885SMN1; SMN2 4375/4885 |
| US-20150004134-A1 | TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | PAM 1524/4885L3MBTL1 3377/4885SMN1; SMN2 4454/4885 |
| US-20050171147-A1 | Sulfonamide derivatives for the treatment of diseases | SULT2A1, STS, SULT1A1 | PAM 710/4885L3MBTL1 4767/4885SMN1; SMN2 697/4885 |
| US-20050215542-A1 | Compounds for the treatment of diseases | LTC4S, LTB4R2, EPX | PAM 1753/4885L3MBTL1 3847/4885SMN1; SMN2 1244/4885 |
| US-20050215590-A1 | Formamide derivatives for the treatment of diseases | FH, FAH, HRH4 | PAM 1149/4885L3MBTL1 4748/4885SMN1; SMN2 1653/4885 |
| US-20130157998-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | PAM 1568/4885L3MBTL1 4146/4885SMN1; SMN2 4375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.